New combo therapy for lupus kidney disease shows promise in asian trial
NCT ID NCT02630628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different drug combinations for people with active lupus nephritis, a serious kidney condition caused by lupus. It compared tacrolimus plus steroids against mycophenolate mofetil plus steroids. The goal was to see which combination better controlled kidney disease and prevented flare-ups. 130 adults from Asia took part in this Phase 3 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a single infusion tame tough lupus?
- Can a smartphone app bridge the lupus care gap for women of color?
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Cancer drug shows promise for lupus kidney disease